|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Narrow-band imaging with magnifying endoscopy is accurate for detecting gastric intestinal metaplasia显示文摘AIM:To investigate the predictive value of narrowband imaging with magnifying endoscopy (NBI-ME) for identifying gastric intestinal metaplasia (GIM) in unselected patients. METHODS:We prospectively evaluated consecutive patients undergoing upper endoscopy for various indications, such as epigastric discomfort/pain, anaemia, gastro-oesophageal reflux disease, suspicion of peptic ulcer disease, or chronic liver diseases. Patients underwent NBI-ME, which was performed by three blinded, experienced endoscopists. In addition, five biopsies (2 antrum, 1 angulus, and 2 corpus) were taken and examined by two pathologists unaware of the endoscopic findings to determine the presence or absence of GIM. The correlation between light blue crest (LBC) appearance and histology was measured. Moreover, we quantified the degree of LBC appearance as less than 20% (+), 20%-80% (++) and more than 80% (+++) of an image field, and the semiquantitative evaluation of LBC appearance was correlated with IM percentage from the histological findings. RESULTS:We enrolled 100 (58 F/42 M) patients who were mainly referred for gastro-esophageal reflux disease/dyspepsia (46%), cancer screening/anaemia (34%), chronic liver disease (9%), and suspected celiac disease (6%); the remaining patients were referred for other indications. The prevalence of Helicobacter pylori (H. pylori ) infection detected from the biopsies was 31%, while 67% of the patients used proton pump inhibitors. LBCs were found in the antrum of 33 patients (33%); 20 of the cases were classified as LBC+, 9 as LBC++, and 4 as LBC+++. LBCs were found in the gastric body of 6 patients (6%), with 5 of them also having LBCs in the antrum. The correlation between the appearance of LBCs and histological GIM was good, with a sensitivity of 80% (95%CI:67-92), a specificity of 96% (95%CI:93-99), a positive predictive value of 84% (95%CI:73-96), a negative predictive value of 95% (95%CI:92-98), and an accuracy of 93% (95%CI:90-97). The NBI-ME examination overlooked GIM in 8 cases, but the GIM was less than 5% in 7 of the cases. Moreover, in the 6 false positive cases, the histological examination showed the presence of reactive gastropathy (4 cases) or H. pylori active chronic gastritis (2 cases). The semiquantitative correlation between the rate of LBC appearance and the percentage of GIM was 79% (P < 0.01). CONCLUSION:NBI-ME achieved good sensitivity and specificity in recognising GIM in an unselected population. In routine clinical practice, this technique can reliably target gastric biopsies. | Edoardo Savarino Marina Corbo Pietro Dulbecco Lorenzo Gemignani Elisa Giambruno Luca Mastracci Federica Grillo Vincenzo Savarino | 2013 | World Journal of Gastroenterology2013，19，17： | 23 |
| 2 | Therapeutic potential of curcumin in digestive diseases显示文摘Curcumin is a low-molecular-weight hydrophobic polyphenol that is extracted from turmeric,which possesses a wide range of biological properties including anti-inflammatory,anti-oxidant,anti-proliferative and anti-microbial activities.Despite its diverse targets and substantial safety,clinical applications of this molecule for digestive disorders have been largely limited to case series or small clinical trials.The poor bioavailability of curcumin is likely the major hurdle for its more widespread use in humans.However,complexation of curcumin into phytosomes has recently helped to bypass this problem,as it has been demonstrated that this new lecithin formulation enables increased absorption to a level 29-fold higher than that of traditional curcuminoid products.This allows us to achieve much greater tissue substance delivery using significantly lower doses of curcumin than have been used in past clinical studies.As curcumin has already been shown to provide good therapeutic results in some small studies of both inflammatory and neoplastic bowel disorders,it is reasonable to anticipate an even greater efficacy with the advent of this new technology,which remarkably improves its bioavailability.These features are very promising and may represent a novel and effective therapeutic approach to both functional and organic digestive diseases. | Pietro Dulbecco Vincenzo Savarino | 2013 | World Journal of Gastroenterology2013，19，48： | 5 |
| 3 | Application of the platelet count/spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis: A validation study based on follow-up显示文摘 | E.G. Giannini F. Botta P. Borro P. Dulbecco E. Testa C. Mansi V. Savarino R. Testa | 2005 | Digestive and Liver Disease2005，，10： | 3 |
| 4 | Safety of cold polypectomy for < 10 mm polyps at colonoscopy: a prospective multicenter study显示文摘 | A. Repici C. Hassan E. Vitetta E. Ferrara G. Manes G. Gullotti A. Princiotta P. Dulbecco N. Gaffuri E. Bettoni N. Pagano G. Rando G. Strangio A. Carlino F. Romeo D. de Paula Pessoa Ferreira A. Zullo L. Ridola A. Malesci | 2012 | Endoscopy2012，，01： | 2 |
| 5 | A study of 4 - and 7 - day triple therapy with rabeprazole, high - dose levofloxacin and tinidazole rescue treatment for Helicobacter pyloi eradication显示文摘 | GIANNINI E G BILARD1 C DULBECCO P | 2006 | Aliment Pharmacol Ther2006，23，2： | 1 |
| 6 | A turning point in cancer research:sequencing the human genome显示文摘 | Dulbecco R | 1986 | Science1986，231，4742： | 1 |
| 7 | A Turning Point in Cancer Research: Sequencing the Human Genome显示文摘 | Dulbecco R | 1986 | Science1986，321，4742： | 1 |
| 8 | OC.06.3 ADALIMUMAB IN ACTIVE ULCERATIVE COLITIS: A “REAL-LIFE” OBSERVATIONAL STUDY显示文摘 | A. Armuzzi L. Biancone M. Daperno A. Coli V. Annese S. Ardizzone P. Balestrieri F. Bossa F. Castiglione M. Cicala S. Danese R. D’Incà P. Dulbecco G. Feliciangeli W. Fries S. Genise P. Gionchetti S. Gozzi A. Kohn R. Lorenzetti M. Milla S. Onali A. Orlando | 2012 | Digestive and Liver Disease2012，，： | 1 |
| 9 | Management strategy forpatients with gastroesophageal reflux disease: a comparison betweenempirical treatment with esomeprazole and endoscopy-orientedtreatment 显示文摘 | Giannini EG Zentilin P Dulbecco P | 2008 | Am J Gastroenterol2008，103，2： | 1 |
| 10 | Management strategy for patients with gastroesophageal reflux disease:a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment 显示文摘 | Giannini EG Zentilin P Dulbecco P | 2008 | Am J Gastroentero12008，103，2： | 1 |
| 11 | Normal values of 24-h ambulatory intraluminal impedance combined with pH-metry in subjects eating a Mediterranean diet显示文摘 | Zentilin P liritano E Dulbecco P | 2006 | Dig Liver Dis2006，38，4： | 1 |
| 12 | Proteomic dissection of dome formation in a mammary cell line显示文摘 | Zucchi I Dulbecco R | 2002 | Mammary Gland Biol Neoplasia2002，7，4： | 1 |
| 13 | Two monoclonal antibodies selective for human mammary carcinoma 显示文摘 | Dulbecco R Allen R | 1985 | Cancer Res1985，45，： | 1 |
| 14 | Atuming poin tincancer research:sequencing the human genume显示文摘 | Dulbecco R | 1986 | Science1986，231，： | 1 |
| 15 | A turning point in cancer research: sequencing the human genome 显示文摘 | Dulbecco R | 1986 | Science1986，231，： | 1 |
| 16 | A study of 4-and 7-day triple therapy with rabeprazole,high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pyloi eradication显示文摘 | Giannini E G Bilardi C Dulbecco P | 2006 | Aliment Pharmacol Ther2006，23，2： | 1 |
| 17 | Production of plaques in monolayer tissue cultures bysingle particles of an animal virus显示文摘 | Dulbecco R | 1952 | Proc Natl Acad Sci USA1952，38，8： | 1 |
| 18 | Prevention of postoperative recurrence of Crohn’s disease by Adalimumab: a case series显示文摘 | Edoardo Savarino Pietro Dulbecco Giorgia Bodini Lorenzo Assandri Vincenzo Savarino | 2012 | European Journal of Gastroenterology & Hepatology2012，，4： | 1 |
| 19 | Some problems of animal virology asstudied by the plaque technique显示文摘 | Dulbecco R Vogt M | 1953 | Cold Spring HarborSymp Quant Biol1953，18，： | 1 |
| 20 | A turning point in cancer research: sequencing the human genome 显示文摘 | DULBECCO R | 1986 | Science1986，231，4742： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员